Laser-based vaccine adjuvants

Abstract

The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.

What is claimed is: 
     
         1 . Use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. 
     
     
         2 . Use of the composition as in  claim 1 , wherein the composition further comprises an amount of HSP 70. 
     
     
         3 . Use of the composition as in  claim 1 , wherein the enhanced immune response is generated from a non-responsive subject. 
     
     
         4 . Use of the composition as in  claim 1 , to generate the enhanced immune response from the subject with an increased HSP 70 concentration. 
     
     
         5 . Use of the composition as in  claim 1 , wherein the non-destructive laser radiation has of a frequency of the laser is about 1 to about 20 kilohertz, a power of the laser is about 1 to about 10 watts, and a pulse duration is about 1 to about 1000 nanoseconds. 
     
     
         6 . Use of the composition as in  claim 1 , wherein the previous exposure to the non-destructive laser radiation was of a wavelength of 510 nm and 578 nm 
     
     
         7 . Use of the composition as in  claim 1 , wherein the previous exposure to the non-destructive laser radiation was from a neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. 
     
     
         8 . Use of the composition as in  claim 1 , wherein the enhanced immune response comprises an increase in an antibody titer specific to the vaccine. 
     
     
         9 . Use of the composition as in  claim 1 , wherein the enhanced immune response comprises an increased resistance to a condition.